Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.03, Bloomberg Earnings reports. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.03 million. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. The company’s revenue for the quarter was up 18.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.66) earnings per share.

Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) traded down $0.30 during mid-day trading on Tuesday, reaching $9.75. The company’s stock had a trading volume of 266,802 shares, compared to its average volume of 381,851. Bellicum Pharmaceuticals has a one year low of $7.41 and a one year high of $23.11. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.34 and a current ratio of 8.34.

Several equities analysts recently weighed in on BLCM shares. BidaskClub raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, September 18th. Finally, Raymond James Financial, Inc. set a $18.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $26.20.

TRADEMARK VIOLATION WARNING: “Bellicum Pharmaceuticals, Inc. (BLCM) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/07/bellicum-pharmaceuticals-inc-blcm-issues-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.